Last reviewed · How we verify
Wobe-Mugos E
Wobe-Mugos E is a combination of a deoxyribonuclease and a ribonuclease inhibitor.
Wobe-Mugos E is an investigational drug being studied for the treatment of stage II and III multiple myeloma. It is a proteolytic enzyme mixture with potential immunomodulatory and anti-inflammatory effects. Currently, there are no FDA-approved labels, but one Phase 3 trial is ongoing.
At a glance
| Generic name | Wobe-Mugos E |
|---|---|
| Sponsor | Medsearch |
| Drug class | Enzyme |
| Target | Deoxyribonuclease, Ribonuclease inhibitor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
This combination helps to break down DNA and prevent its degradation, which can be beneficial in certain medical conditions. The ribonuclease inhibitor helps to prevent the breakdown of RNA, which is also important for cellular function.
Approved indications
- Cystic fibrosis
Common side effects
- Hypersensitivity reactions
- Respiratory infections
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Wobe-Mugos E CI brief — competitive landscape report
- Wobe-Mugos E updates RSS · CI watch RSS
- Medsearch portfolio CI